Poli (propilen fumarat) - vinil fosfonik asit bazlı ilaç salım sistemleri

Poly (propylene fumarate) (PPF) and vinyl phosphonic acid (VPA) based nanoparticles were developed as drug delivery vehicles within the scope of this study. In addition, studies on folic acid conjugation to PPF and the preparation of PPF-FA and VPA based nanoparticles were also carried out due to folic acid's known specifity against cancer cells. Thus, first PPF pre-polymer was synthesized via poly condensation of fumaric acid and an excess of propylene glycol then PPF was copolymerized with VPA in 70/30 weight ratio via UV mini-emulsion polymerization to produce PPF/VPA nanoparticles. The highest gel content of 87.6 percent and particle formation in the 500 nm to 2000 nm size range were achieved under the optimized reaction conditions using 3 weight percent BAPO initiator, 0.04 weight percent TAA co-catalyst with 9 weight percent SDS surfactant applying 2 hours of UV cure with 10 minutes of homogenization time at 1000 rpm. The completion of cure reaction was confirmed via DSC analysis. Degradation profiles of the PPF/VPA particles in PBS buffer solution (pH=7.4) showed that 88 to 98 percent of the particles degraded in 84 days depending on the homogenization time, whereas the pH dropped from 7.4 to 2.9 to 3.3 at the end of 89 days. PPF/VPA nanoparticles were also prepared in the presence of the model anti-cancer drug Paclitaxel. Paclitaxel release from the PPF/VPA particles resulted in linear and prolonged release which was degradation controlled. PPF-Folic Acid (PPF-FA) conjugate was synthesized via the addition of FA to PPF pre-polymer in the presence of dehydrant: dicyclo hexyl carbodiimide (DCC) and catalyst. 4-dimethyl amino pyridine (DMAP). The PPF-FA pre-polymer was characterized via FT-IR and 1H-NMR spectroscopy. UV mini emulsion polymerization of PPF-FA with VPA resulted in microplate morphology with nanoparticles which showed variation with surfactant concentration.